Immunic Inc (IMUX) is a clinical-stage biopharmaceutical company focused on developing novel therapies for chronic inflammatory and autoimmune diseases. The company's lead drug candidate is IMU-838, an oral, small molecule inhibitor of dihydroorotate dehydrogenase (DHODH) in development for multiple sclerosis, ulcerative colitis, and COVID-19. IMU-838 has shown promising results in preclinical studies, and the company is currently conducting clinical trials to evaluate its safety and efficacy. In addition to IMU-838, Immunic has a pipeline of other drug candidates targeting a range of inflammatory and autoimmune diseases. The company is headquartered in New York City.
Immunic Inc (IMUX) is a clinical-stage biopharmaceutical company focused on developing novel therapies for chronic inflammatory and autoimmune diseases. The company's lead drug candidate is IMU-838, an oral, small molecule inhibitor of dihydroorotate dehydrogenase (DHODH) in development for multiple sclerosis, ulcerative colitis, and COVID-19. IMU-838 has shown promising results in preclinical studies, and the company is currently conducting clinical trials to evaluate its safety and efficacy. In addition to IMU-838, Immunic has a pipeline of other drug candidates targeting a range of inflammatory and autoimmune diseases. The company is headquartered in New York City.